Tag: Adalimumab
-
Mabwell’s Adalimumab Biosimilar Gains Marketing Approval in Indonesia
Overview: Mabwell’s Adalimumab Biosimilar Approved in Indonesia In a significant milestone for global biopharmaceutical access, Mabwell announced that its Adalimumab Injection 9MW0113—marketed as JUNMAIKANG in China—has received marketing approval in Indonesia. The decision marks the company’s first major regulatory clearance in Southeast Asia for a biosimilar of adalimumab, a leading anti-TNF therapy used to treat…
-
Mabwell Adalimumab Biosimilar Approved in Indonesia
Indonesia Grants Marketing Approval for Mabwell’s Adalimumab Biosimilar In a move that could broaden access to biologic therapies for autoimmune conditions, Mabwell, a Shanghai-based biopharmaceutical company, announced that its Adalimumab Injection 9MW0113 (marketed as JUNMAIKANG in China) has received marketing approval in Indonesia. The approval marks a key milestone for Mabwell’s global expansion strategy and…
-
Mabwell Adalimumab Biosimilar Approved in Indonesia, Expands Southeast Asia Reach
Overview: Mabwell’s Adalimumab Biosimilar Gains Indonesian Marketing Approval Mabwell, a Shanghai-based biopharmaceutical company renowned for its integrated development-to-manufacturing approach, has secured marketing approval in Indonesia for its Adalimumab Injection 9MW0113, marketed as JUNMAIKANG in China. The green light from Indonesian regulators marks a significant milestone for Mabwell’s global expansion and for patients in Southeast Asia…